Cetuximab  	Cetuximab  	 NNP	B-NP
for  	for  	 IN	O
the  	the  	 DT	O
treatment  	treatment  	 NN	O
of  	of  	 IN	O
recurrent  	recurrent  	 NN	O
and 	and 	 CC	O
/ 	/ 	 NNP	O
or  	or  	 CC	O
metastatic  	metastatic  	 JJ	B-NP
squamous  	squamous  	 JJ	I-NP
cell  	cell  	 NN	I-NP
carcinoma  	carcinoma  	 NN	I-NP
of  	of  	 IN	O
the  	the  	 DT	O
head  	head  	 NN	O
and  	and  	 CC	O
neck  	neck  	 NN	O
This  	This  	 DT	O
paper  	paper  	 NN	O
presents  	presents  	 VBZ	O
a  	a  	 DT	O
summary  	summary  	 NN	O
of  	of  	 IN	O
the  	the  	 DT	O
evidence  	evidence  	 NN	B-NP
review  	review  	 NN	I-NP
group  	group  	 NN	I-NP
( 	( 	 -LRB-	O
ERG 	ERG 	 NNP	O
)  	)  	 -RRB-	O
report  	report  	 NN	O
into  	into  	 IN	O
the  	the  	 DT	O
clinical  	clinical  	 JJ	B-NP
effectiveness  	effectiveness  	 NN	I-NP
and  	and  	 CC	O
cost-effectiveness  	cost-effectiveness  	 JJ	B-NP
of  	of  	 IN	I-NP
cetuximab  	cetuximab  	 NN	I-NP
for  	for  	 IN	O
recurrent  	recurrent  	 NN	O
and 	and 	 CC	O
/ 	/ 	 NNP	O
or  	or  	 CC	O
metastatic  	metastatic  	 JJ	B-NP
squamous  	squamous  	 JJ	I-NP
cell  	cell  	 NN	I-NP
carcinoma  	carcinoma  	 NN	I-NP
of  	of  	 IN	O
the  	the  	 DT	O
head  	head  	 NN	O
and  	and  	 CC	O
neck  	neck  	 NN	O
( 	( 	 -LRB-	O
SCCHN 	SCCHN 	 NNP	B-NP
)  	)  	 -RRB-	O
based  	based  	 VBN	O
upon  	upon  	 IN	O
a  	a  	 DT	O
review  	review  	 NN	O
of  	of  	 IN	O
the  	the  	 DT	O
manufacturer 	manufacturer 	 NN	O
's  	's  	 POS	O
submission  	submission  	 NN	O
to  	to  	 TO	O
the  	the  	 DT	O
National  	National  	 NNP	O
Institute  	Institute  	 NNP	O
for  	for  	 IN	O
Health  	Health  	 NNP	O
and  	and  	 CC	O
Clinical  	Clinical  	 NNP	B-NP
Excellence  	Excellence  	 NNP	I-NP
( 	( 	 -LRB-	O
NICE 	NICE 	 NNP	O
)  	)  	 -RRB-	O
as  	as  	 IN	O
part  	part  	 NN	O
of  	of  	 IN	O
the  	the  	 DT	O
single  	single  	 JJ	B-NP
technology  	technology  	 NN	I-NP
appraisal  	appraisal  	 NN	I-NP
( 	( 	 -LRB-	O
STA 	STA 	 NNP	B-NP
)  	)  	 -RRB-	O
process 	process 	 NN	O
.  	.  	 .	O
The  	The  	 DT	O
submission 	submission 	 NN	O
's  	's  	 POS	O
evidence  	evidence  	 NN	O
came  	came  	 VBD	O
from  	from  	 IN	O
a  	a  	 DT	O
single  	single  	 JJ	O
reasonably  	reasonably  	 RB	O
high-quality  	high-quality  	 JJ	B-NP
randomised  	randomised  	 NNS	O
controlled  	controlled  	 VBN	B-NP
trial  	trial  	 NN	I-NP
( 	( 	 -LRB-	O
RCT 	RCT 	 NNP	B-NP
)  	)  	 -RRB-	O
[ 	[ 	 -LRB-	O
EXTREME  	EXTREME  	 NNP	O
( 	( 	 -LRB-	O
Erbitux  	Erbitux  	 NNP	B-NP
in  	in  	 IN	O
First-Line  	First-Line  	 NNP	B-NP
Treatment  	Treatment  	 NNP	I-NP
of  	of  	 IN	O
Recurrent  	Recurrent  	 NNP	O
or  	or  	 CC	O
Metastatic  	Metastatic  	 NNP	B-NP
Head  	Head  	 NNP	I-NP
and  	and  	 CC	O
Neck  	Neck  	 NNP	O
Cancer 	Cancer 	 NNP	O
) 	) 	 -RRB-	O
;  	;  	 :	O
n  	n  	 CD	O
=  	=  	 SYM	O
442 	442 	 CD	O
]  	]  	 -RRB-	O
comparing  	comparing  	 FW	B-NP
cetuximab  	cetuximab  	 FW	I-NP
plus  	plus  	 FW	O
chemotherapy  	chemotherapy  	 FW	O
( 	( 	 -LRB-	O
CTX 	CTX 	 NNP	B-NP
)  	)  	 -RRB-	O
with  	with  	 IN	O
CTX  	CTX  	 NNP	B-NP
alone 	alone 	 RB	O
.  	.  	 .	O
Cetuximab  	Cetuximab  	 NNP	B-NP
plus  	plus  	 CC	O
CTX  	CTX  	 NNP	B-NP
had  	had  	 VBD	O
significant  	significant  	 JJ	O
effects  	effects  	 NNS	O
compared  	compared  	 VBN	O
with  	with  	 IN	O
CTX  	CTX  	 NNP	B-NP
alone  	alone  	 RB	O
on  	on  	 IN	O
the  	the  	 DT	O
primary  	primary  	 JJ	B-NP
outcome  	outcome  	 NN	I-NP
of  	of  	 IN	O
overall  	overall  	 JJ	O
survival  	survival  	 NN	O
( 	( 	 -LRB-	O
10.1  	10.1  	 CD	O
versus  	versus  	 CD	O
7.4  	7.4  	 CD	O
months  	months  	 NNS	O
respectively 	respectively 	 RB	O
)  	)  	 -RRB-	O
and  	and  	 CC	O
the  	the  	 DT	O
secondary  	secondary  	 JJ	B-NP
outcomes  	outcomes  	 NNS	I-NP
of  	of  	 IN	I-NP
progression-free  	progression-free  	 JJ	I-NP
survival  	survival  	 NN	I-NP
( 	( 	 -LRB-	O
PFS 	PFS 	 NNP	B-NP
)  	)  	 -RRB-	O
( 	( 	 -LRB-	O
5.6  	5.6  	 CD	O
versus  	versus  	 CD	O
3.3  	3.3  	 CD	O
months 	months 	 NNS	O
) 	) 	 -RRB-	O
,  	,  	 ,	O
best  	best  	 RBS	O
overall  	overall  	 JJ	O
response  	response  	 NN	O
to  	to  	 TO	O
therapy  	therapy  	 VB	O
( 	( 	 -LRB-	O
35.6 	35.6 	 CD	O
%  	%  	 NN	O
versus  	versus  	 IN	O
19.5 	19.5 	 CD	O
% 	% 	 NN	O
) 	) 	 -RRB-	O
,  	,  	 ,	O
disease  	disease  	 NN	B-NP
control  	control  	 NN	I-NP
rate  	rate  	 NN	I-NP
( 	( 	 -LRB-	O
81.1 	81.1 	 NNP	O
%  	%  	 NN	O
versus  	versus  	 IN	O
60 	60 	 CD	O
% 	% 	 NN	O
)  	)  	 -RRB-	O
and  	and  	 CC	O
time-to-treatment  	time-to-treatment  	 JJ	B-NP
failure  	failure  	 NN	I-NP
( 	( 	 -LRB-	O
4.8  	4.8  	 CD	O
versus  	versus  	 CD	O
3.0  	3.0  	 CD	O
months 	months 	 NNS	O
) 	) 	 -RRB-	O
,  	,  	 ,	O
but  	but  	 CC	O
not  	not  	 RB	O
on  	on  	 IN	O
duration  	duration  	 NN	O
of  	of  	 IN	O
response  	response  	 NN	O
( 	( 	 -LRB-	O
5.6  	5.6  	 CD	O
months  	months  	 NNS	O
versus  	versus  	 IN	O
4.7  	4.7  	 CD	O
months 	months 	 NNS	O
) 	) 	 -RRB-	O
.  	.  	 .	O
No  	No  	 DT	O
safety  	safety  	 NN	O
issues  	issues  	 NNS	O
with  	with  	 IN	O
cetuximab  	cetuximab  	 NN	B-NP
arose  	arose  	 VBD	O
beyond  	beyond  	 IN	O
those  	those  	 DT	O
already  	already  	 RB	O
previously  	previously  	 RB	O
documented 	documented 	 VBN	O
.  	.  	 .	O
The  	The  	 DT	O
manufacturer  	manufacturer  	 NN	B-NP
developed  	developed  	 VBD	O
a  	a  	 DT	O
two-arm  	two-arm  	 JJ	B-NP
state-transition  	state-transition  	 JJ	I-NP
Markov  	Markov  	 JJ	I-NP
model  	model  	 NN	I-NP
to  	to  	 TO	O
evaluate  	evaluate  	 VB	O
the  	the  	 DT	O
cost-effectiveness  	cost-effectiveness  	 JJ	B-NP
of  	of  	 IN	I-NP
cetuximab  	cetuximab  	 FW	I-NP
plus  	plus  	 FW	O
CTX  	CTX  	 FW	B-NP
versus  	versus  	 FW	O
CTX  	CTX  	 NNP	B-NP
alone 	alone 	 RB	O
,  	,  	 ,	O
using  	using  	 VBG	O
clinical  	clinical  	 JJ	B-NP
data  	data  	 NNS	I-NP
from  	from  	 IN	O
the  	the  	 DT	O
EXTREME  	EXTREME  	 NNP	O
trial 	trial 	 NN	O
.  	.  	 .	O
The  	The  	 DT	O
ERG  	ERG  	 NNP	O
recalculated  	recalculated  	 VBD	O
the  	the  	 DT	O
base-case  	base-case  	 JJ	B-NP
cost-effectiveness  	cost-effectiveness  	 JJ	I-NP
results  	results  	 NNS	I-NP
taking  	taking  	 VBG	O
changes  	changes  	 NNS	O
in  	in  	 IN	O
parameters  	parameters  	 NNS	O
and  	and  	 CC	O
assumptions  	assumptions  	 NNS	O
into  	into  	 IN	O
account 	account 	 NN	O
.  	.  	 .	O
Subgroup  	Subgroup  	 NNP	B-NP
and  	and  	 CC	O
threshold  	threshold  	 NN	B-NP
analyses  	analyses  	 NNS	I-NP
were  	were  	 VBD	O
also  	also  	 RB	O
explored 	explored 	 VBN	O
.  	.  	 .	O
The  	The  	 DT	O
manufacturer  	manufacturer  	 NN	B-NP
reported  	reported  	 VBD	O
an  	an  	 DT	O
incremental  	incremental  	 JJ	B-NP
cost-effectiveness  	cost-effectiveness  	 JJ	I-NP
ratio  	ratio  	 NN	I-NP
( 	( 	 -LRB-	O
ICER 	ICER 	 NNP	B-NP
)  	)  	 -RRB-	O
of  	of  	 IN	O
121,367  	121,367  	 CD	O
pounds  	pounds  	 NNS	O
per  	per  	 IN	O
quality-adjusted  	quality-adjusted  	 JJ	B-NP
life-year  	life-year  	 NN	I-NP
( 	( 	 -LRB-	O
QALY 	QALY 	 NNP	B-NP
)  	)  	 -RRB-	O
gained  	gained  	 VBD	O
and  	and  	 CC	O
an  	an  	 DT	O
incremental  	incremental  	 JJ	B-NP
cost  	cost  	 NN	I-NP
per  	per  	 IN	O
life-year  	life-year  	 NNP	B-NP
gained  	gained  	 VBD	O
of  	of  	 IN	O
92,226  	92,226  	 CD	O
pounds 	pounds 	 NNS	O
.  	.  	 .	O
Univariate  	Univariate  	 JJ	B-NP
sensitivity  	sensitivity  	 NN	I-NP
analysis  	analysis  	 NN	I-NP
showed  	showed  	 VBD	O
that  	that  	 IN	O
varying  	varying  	 VBG	O
the  	the  	 DT	O
cost  	cost  	 NN	O
of  	of  	 IN	O
day-case  	day-case  	 JJ	B-NP
infusion  	infusion  	 NN	I-NP
and  	and  	 CC	O
the  	the  	 DT	O
utility  	utility  	 NN	B-NP
values  	values  	 NNS	I-NP
in  	in  	 IN	O
the  	the  	 DT	O
stable 	stable 	 JJ	B-NP
/ 	/ 	 CD	I-NP
response  	response  	 NN	I-NP
health  	health  	 NN	I-NP
state  	state  	 NN	I-NP
of  	of  	 IN	I-NP
the  	the  	 DT	I-NP
cetuximab  	cetuximab  	 NN	I-NP
plus  	plus  	 CC	O
CTX  	CTX  	 NNP	B-NP
arm  	arm  	 NN	I-NP
had  	had  	 VBD	O
the  	the  	 DT	O
greatest  	greatest  	 JJS	O
impact  	impact  	 NN	O
on  	on  	 IN	O
the  	the  	 DT	O
ICER 	ICER 	 NNP	B-NP
.  	.  	 .	O
Probabilistic  	Probabilistic  	 JJ	B-NP
sensitivity  	sensitivity  	 NN	I-NP
analysis  	analysis  	 NN	I-NP
illustrated  	illustrated  	 VBD	O
that  	that  	 DT	O
cetuximab  	cetuximab  	 NN	B-NP
plus  	plus  	 CC	O
CTX  	CTX  	 NNP	B-NP
is  	is  	 VBZ	O
unlikely  	unlikely  	 JJ	O
to  	to  	 TO	O
be  	be  	 VB	O
cost-effective  	cost-effective  	 JJ	O
for  	for  	 IN	O
patients  	patients  	 NNS	O
with  	with  	 IN	O
recurrent  	recurrent  	 NN	O
and 	and 	 CC	O
/ 	/ 	 NNP	O
or  	or  	 CC	O
metastatic  	metastatic  	 JJ	B-NP
SCCHN 	SCCHN 	 NNP	I-NP
,  	,  	 ,	O
even  	even  	 RB	O
at  	at  	 IN	O
what  	what  	 WP	O
would  	would  	 MD	O
usually  	usually  	 RB	O
be  	be  	 VB	O
considered  	considered  	 VBN	O
very  	very  	 RB	O
high  	high  	 JJ	O
levels  	levels  	 NNS	O
of  	of  	 IN	O
willingness  	willingness  	 NN	O
to  	to  	 TO	O
pay  	pay  	 VB	O
for  	for  	 IN	O
an  	an  	 DT	O
additional  	additional  	 JJ	O
QALY 	QALY 	 NNP	B-NP
.  	.  	 .	O
With  	With  	 IN	O
regard  	regard  	 NN	O
to  	to  	 TO	O
the  	the  	 DT	O
economic  	economic  	 JJ	B-NP
model  	model  	 NN	I-NP
the  	the  	 DT	O
appropriateness  	appropriateness  	 NN	B-NP
and  	and  	 CC	O
reliability  	reliability  	 NN	O
of  	of  	 IN	O
parametric  	parametric  	 JJ	B-NP
survival  	survival  	 NN	I-NP
projection  	projection  	 NN	I-NP
beyond  	beyond  	 IN	O
the  	the  	 DT	O
duration  	duration  	 NN	O
of  	of  	 IN	O
trial  	trial  	 NN	B-NP
data  	data  	 NNS	I-NP
could  	could  	 MD	O
not  	not  	 RB	O
be  	be  	 VB	O
fully  	fully  	 RB	O
explored  	explored  	 VBN	O
because  	because  	 IN	O
of  	of  	 IN	O
lack  	lack  	 NN	O
of  	of  	 IN	O
information 	information 	 NN	O
.  	.  	 .	O
The  	The  	 DT	O
ERG  	ERG  	 NNP	O
also  	also  	 RB	O
questioned  	questioned  	 VBD	O
the  	the  	 DT	O
appropriateness  	appropriateness  	 NN	B-NP
of  	of  	 IN	I-NP
economic  	economic  	 JJ	I-NP
modelling  	modelling  	 NN	I-NP
in  	in  	 IN	O
this  	this  	 DT	O
STA  	STA  	 NNP	B-NP
as  	as  	 IN	O
evidence  	evidence  	 NN	O
is  	is  	 VBZ	O
available  	available  	 JJ	O
only  	only  	 JJ	O
from  	from  	 IN	O
a  	a  	 DT	O
single  	single  	 JJ	O
RCT 	RCT 	 NNP	B-NP
.  	.  	 .	O
In  	In  	 IN	O
conclusion 	conclusion 	 NN	O
,  	,  	 ,	O
the  	the  	 DT	O
ERG  	ERG  	 NNP	O
considers  	considers  	 VBZ	O
that  	that  	 IN	O
patients  	patients  	 NNS	O
with  	with  	 IN	O
metastatic  	metastatic  	 JJ	B-NP
SCCHN  	SCCHN  	 NNP	I-NP
were  	were  	 VBD	O
not  	not  	 RB	O
shown  	shown  	 VBN	O
to  	to  	 TO	O
receive  	receive  	 VB	O
a  	a  	 DT	O
significant  	significant  	 JJ	O
survival  	survival  	 NN	B-NP
benefit  	benefit  	 NN	I-NP
from  	from  	 IN	O
cetuximab  	cetuximab  	 NN	B-NP
plus  	plus  	 CC	O
CTX  	CTX  	 NNP	B-NP
compared  	compared  	 VBN	O
with  	with  	 IN	O
CTX  	CTX  	 NNP	B-NP
alone  	alone  	 RB	O
and  	and  	 CC	O
that  	that  	 IN	O
even  	even  	 RB	O
setting  	setting  	 VBG	O
a  	a  	 DT	O
lower  	lower  	 JJR	O
price  	price  	 NN	O
for  	for  	 IN	O
cetuximab  	cetuximab  	 NNS	B-NP
would  	would  	 MD	O
not  	not  	 RB	O
strengthen  	strengthen  	 VB	O
the  	the  	 DT	O
manufacturer 	manufacturer 	 NN	O
's  	's  	 POS	O
case  	case  	 NN	O
for  	for  	 IN	O
cost-effectiveness 	cost-effectiveness 	 JJ	B-NP
.  	.  	 .	O
